Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 39, 2015, Pages 12217-12222

  Megchelenbrink, Wout ^a,b   Katzir, Rotem ^c   Lu, Xiaowen ^b   Ruppin, Eytan ^c,d   Notebaart, Richard A ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c University of Maryland ^*  (United States)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Genetic interactions; Human metabolism; Synthetic dosage lethality; Systems biology

Indexed keywords

ESTROGEN RECEPTOR; SHORT HAIRPIN RNA;

ARTICLE; BIOMASS; BREAST CANCER; CANCER CELL LINE; CANCER SURVIVAL; CELL GROWTH; CITRIC ACID CYCLE; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE OVEREXPRESSION; GLUCOSE UTILIZATION; GLYCOGEN METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHALITY; MAJOR CLINICAL STUDY; METABOLISM; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; SYNTHETIC DOSAGE LETHALITY; TUMOR GROWTH; TUMOR VOLUME; BIOLOGICAL MODEL; COMPUTER SIMULATION; GENE EXPRESSION REGULATION; GENETICS; LETHAL GENE; NEOPLASM; ONCOGENE; PHYSIOLOGY; PROCEDURES; SYSTEMS BIOLOGY; TUMOR SUPPRESSOR GENE;

COMPUTER SIMULATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, LETHAL; GENES, TUMOR SUPPRESSOR; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, GENETIC; NEOPLASMS; ONCOGENES; SYSTEMS BIOLOGY;

EID: 84942693276     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1508573112     Document Type: Article

References (45)

1. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH (1997) Integrating genetic approaches into the discovery of anticancer drugs. Science 278(5340):1064-1068.
2. Costanzo M, et al. (2010) The genetic landscape of a cell. Science 327(5964):425-431.
3. Szappanos B, et al. (2011) An integrated approach to characterize genetic interaction networks in yeast metabolism. Nat Genet 43(7):656-662.
4. Suthers PF, Zomorrodi A, Maranas CD (2009) Genome-scale gene/reaction essentiality and synthetic lethality analysis. Mol Syst Biol 5:301.
5. Deutscher D, Meilijson I, Kupiec M, Ruppin E (2006) Multiple knockout analysis of genetic robustness in the yeast metabolic network. Nat Genet 38(9):993-998.
6. Segrè D, Deluna A, Church GM, Kishony R (2005) Modular epistasis in yeast metabolism. Nat Genet 37(1):77-83.
7. Folger O, et al. (2011) Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7:501.
8. Frezza C, et al. (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumaratehydratase. Nature 477(7363):225-228.
9. Laufer C, Fischer B, Billmann M, Huber W, Boutros M (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. Nat Methods 10(5):427-431.
10. Luo J, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137(5):835-848.
11. Lu X, Kensche PR, Huynen MA, Notebaart RA (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. Nat Commun 4:2124.
12. Kaelin WG Jr (2005) The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5(9):689-698.
13. Rehman FL, Lord CJ, Ashworth A (2010) Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 7(12):718-724.
14. Chan DA, Giaccia AJ (2011) Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 10(5):351-364.
15. Kroll ES, Hyland KM, Hieter P, Li JJ (1996) Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 143(1):95-102.
16. Bian Y, et al. (2014) Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors. Proc Natl Acad Sci USA 111(4):1628-1633.
17. Sajesh BV, Guppy BJ, McManus KJ (2013) Synthetic genetic targeting of genome instability in cancer. Cancers (Basel) 5(3):739-761.
18. Sopko R, et al. (2006) Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell 21(3):319-330.
19. Wagner A, et al. (2013) Computational evaluation of cellular metabolic costs successfully predicts genes whose expression is deleterious. Proc Natl Acad Sci USA 110(47): 19166-19171.
20. Jerby-Arnon L, et al. (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158(5):1199-1209.
21. Mo ML, Jamshidi N, Palsson BØ (2007) A genome-scale, constraint-based approach to systems biology of human metabolism. Mol Biosyst 3(9):598-603.
22. Schellenberger J, et al. (2011) Quantitative prediction of cellular metabolism with constraint-based models: The COBRA Toolbox v2.0. Nat Protoc 6(9):1290-1307.
23. Price ND, Papin JA, Schilling CH, Palsson BO (2003) Genome-scale microbial in silico models: The constraints-based approach. Trends Biotechnol 21(4):162-169.
24. Thiele I, et al. (2013) A community-driven global reconstruction of human metabolism. Nat Biotechnol 31(5):419-425.
25. Terzer M, Maynard ND, Covert MW, Stelling J (2009) Genome-scale metabolic networks. Wiley Interdiscip Rev Syst Biol Med 1(3):285-297.
26. Feist AM, Palsson BØ (2008) The growing scope of applications of genome-scale metabolic reconstructions using Escherichia coli. Nat Biotechnol 26(6):659-667.
27. Oberhardt MA, Palsson BØ, Papin JA (2009) Applications of genome-scale metabolic reconstructions. Mol Syst Biol 5:320.
28. Price ND, Reed JL, Palsson BØ (2004) Genome-scale models of microbial cells: Evaluating the consequences of constraints. Nat Rev Microbiol 2(11):886-897.
29. Nam H, et al. (2012) Network context and selection in the evolution to enzyme specificity. Science 337(6098):1101-1104.
30. Notebaart RA, et al. (2014) Network-level architecture and the evolutionary potential of underground metabolism. Proc Natl Acad Sci USA 111(32):11762-11767.
31. Jerby L, et al. (2012) Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res 72(22):5712-5720.
32. Agren R, et al. (2012) Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLOS Comput Biol 8(5):e1002518.
33. Jerby L, Ruppin E (2012) Predicting drug targets and biomarkers of cancer via genomescale metabolic modeling. Clin Cancer Res 18(20):5572-5584.
34. Gatto F, Nookaew I, Nielsen J (2014) Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc Natl Acad Sci USA 111(9):E866-E875.
35. Varma A, Palsson BO (1994) Stoichiometric flux balance models quantitatively predict growth and metabolic by-product secretion in wild-type Escherichia coli W3110. Appl Environ Microbiol 60(10):3724-3731.
36. Favaro E, et al. (2012) Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 16(6): 751-764.
37. Marcotte R, et al. (2012) Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2(2):172-189.
38. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
39. Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534-555.
40. Lu X, Megchelenbrink W, Notebaart RA, Huynen MA (2015) Predicting human genetic interactions from cancer genome evolution. PLoS One 10(5):e0125795.
41. Curtis C, et al.; METABRIC Group (2012) The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486(7403):346-352, 10.1038/nature10983.
42. Gyorffy B, Lánczky A, Szállási Z (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19(2):197-208.
43. Bland JM, Altman DG (2004) The logrank test. BMJ 328(7447):1073.
44. Yang L, et al. (2014) Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 10(5):728, 10.1002/msb.20134892.
45. Duarte NC, et al. (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 104(6):1777-1782.